Scholarlink

<p>The oncogenic role of RUNX1 in epithelial tumors is increasingly recognized, however, its function and mechanism within the tumor immune microenvironment (TME) of colorectal cancer (CRC) remain unclear. This study investigates the contribution of RUNX1 to TME remodeling in CRC. Analysis of clinical CRC tissues revealed that RUNX1 expression is negatively correlated with GITRL levels in tumor cells and is associated with increased infiltration of Treg cells. Functional studies demonstrated that RUNX1 impairs GITRL-GITR signaling, thereby promoting Treg cell infiltration while suppressing CD8<sup>+</sup> T cell activation. Consequently, elevated RUNX1 expression enhanced the sensitivity of CRC tumors to GITR agonistic antibody therapy in a C57BL/6J mouse model. Mechanistically, RUNX1 interacts with STAT1 to inhibit its dimerization and subsequent transcriptional activation of GITRL, thereby suppressing GITRL expression. Our findings highlight the RUNX1/STAT1/GITRL axis as a potential therapeutic target for GITR-based immunotherapy in CRC.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

RUNX1 restrains STAT1-GITRL signaling to shape an immunosuppressive CRC microenvironment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月25日

查看全文
  • Wenting He,
  • Lisheng Zheng,
  • Weiye Huang,
  • Keren Li,
  • Yitian Chen,
  • Rui Zeng,
  • Zhihao Lin,
  • Yangwei Xu,
  • Shengfeng Hu,
  • Qingling Zhang

摘要

The oncogenic role of RUNX1 in epithelial tumors is increasingly recognized, however, its function and mechanism within the tumor immune microenvironment (TME) of colorectal cancer (CRC) remain unclear. This study investigates the contribution of RUNX1 to TME remodeling in CRC. Analysis of clinical CRC tissues revealed that RUNX1 expression is negatively correlated with GITRL levels in tumor cells and is associated with increased infiltration of Treg cells. Functional studies demonstrated that RUNX1 impairs GITRL-GITR signaling, thereby promoting Treg cell infiltration while suppressing CD8+ T cell activation. Consequently, elevated RUNX1 expression enhanced the sensitivity of CRC tumors to GITR agonistic antibody therapy in a C57BL/6J mouse model. Mechanistically, RUNX1 interacts with STAT1 to inhibit its dimerization and subsequent transcriptional activation of GITRL, thereby suppressing GITRL expression. Our findings highlight the RUNX1/STAT1/GITRL axis as a potential therapeutic target for GITR-based immunotherapy in CRC.